Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF, as of
- 24,069 shares
-
€2,483,094.99
It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:
- 12,751 shares
-
€3,137,934.80
Between
- 2,466 purchase transactions
- 2,235 sell transactions
Under the same period, the volumes traded represented:
-
296,190 shares and
€29,245,027.80 t o the purchase -
299,127 shares and
€29,692,331.70 t o the sell
Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of
View source version on businesswire.com: https://www.businesswire.com/news/home/20230106005009/en/
Investors
Vice President, Investor Relations
+44 (0)7584 349 193
Investor Relations Manager
+33 6 64 26 17 49
Media
Vice President and Head of Corporate Brand Strategy
and Communications
+41 79 576 07 23
Senior Manager,
Global Media Relations
+ 33 6 69 09 12 96
Source: Ipsen